Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $29.1429.

KMTS has been the subject of a number of research reports. Piper Sandler lifted their price objective on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th. BTIG Research initiated coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target for the company. The Goldman Sachs Group raised their price objective on shares of Kestra Medical Technologies from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Saturday, December 13th. Finally, Wells Fargo & Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th.

Kestra Medical Technologies Trading Up 2.0%

Shares of NASDAQ:KMTS opened at $26.97 on Wednesday. The firm has a fifty day moving average of $26.29 and a two-hundred day moving average of $21.37. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The firm has a market capitalization of $1.57 billion and a P/E ratio of -8.51.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently bought and sold shares of the business. Eventide Asset Management LLC bought a new position in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $6,853,000. Alyeska Investment Group L.P. bought a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $2,492,000. Yu Fan bought a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $56,880,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Kestra Medical Technologies in the first quarter worth $2,492,000. Finally, Franklin Resources Inc. boosted its holdings in shares of Kestra Medical Technologies by 32.4% during the 2nd quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock worth $7,318,000 after buying an additional 108,103 shares during the period.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.